Abstract
In the previous PIPE-1 project (2021/00979-3), we validated the scaled production process of a batch of nanotechnology-based eye drops for the topical pharmacological treatment (eye drops) of diabetic retinopathy. It is a formulation made up of liposomal nanometric particles incorporating the active ingredient (tempol nitroxide) (not included in the Brazilian or global pharmacopoeia) with…